Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical imiquimod for cervical intraepithelial neoplasia
IRCT20250710066441N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Aug 2025
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Histological regression of cervical intraepithelial neoplasia, Complete histological remission and 4 more. Started Aug 2025; status: completed.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on IRCT20250710066441N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250710066441N1.